Gene · 11096
ADAMTS5: ADAM metallopeptidase with thrombospondin type 1 motif 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADAMTS5: ADAM metallopeptidase with thrombospondin type 1 motif 5. Genes, record 11096. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/11096
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UNA0 | A disintegrin and metalloproteinase with thrombospondin motifs 5 | 930 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026102819 A | 2026-06-23 | 149 | Q9UNA0 | Espacenet |
| EP 4729612 A2 | 2026-04-22 | 67 | Q9UNA0 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36462 | Q9UNA0 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3243 | Q9UNA0 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2818 | Q9UNA0 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 362 | Q9UNA0 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5395 | Q9UNA0 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5395 | Q9UNA0 | Espacenet |
| EP 4583904 A1 | 2025-07-16 | 140 | Q9UNA0 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 2818 | Q9UNA0 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| ALDUMASTAT | CHEMBL4650334 | ADAMTS5 inhibitor | INHIBITOR |
Source ChEMBL
Trials2
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT03595618 | ALDUMASTAT | PHASE2 | 2021-05-12 | ClinicalTrials.gov |
| NCT03311009 | ALDUMASTAT | PHASE1 | ClinicalTrials.gov |
NIH grants963
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADAMTS5 papers | Newest fiscal year |
|---|---|---|---|
| R01AR060364 | Molecular Pathways of Pain Generation in Osteoarthritis | 7 | 2025 |
| R01AG044034 | Oxidative Stress and the Development of Osteoarthritis | 6 | 2025 |
| P30AR074992 | RESOURCE BASED CENTER FOR MUSCULOSKELETAL BIOLOGY AND MEDICINE | 5 | 2025 |
| R01AR064251 | Osteoarthritis Progression And Sensory Pathway Alterations | 5 | 2025 |
| P30AG028716 | Duke Claude D. Pepper Older Americans Independence Center | 4 | 2025 |
| P30AR073752 | Washington University Rheumatic Diseases Research Resource-based Center | 4 | 2025 |
| P30EY010572 | Ophthalmology Core Facility | 4 | 2025 |
| T32AR060719 | Skeletal Disorders Training Program | 4 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 3 | 2025 |
| R01HL160802 | Proteoglycan Metabolism During Cardiac Valve Development and Disease | 3 | 2025 |
1 to 10 of 963Source NIH's project files
See all 963 nih grantsPapers3,260
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hierarchical Nanorocket for spatially coordinated regulation of glycosaminoglycan deposition and metabolism in cartilage. | Bioact Mater | 2027 | 42733560 | PubTator, text mining | PubMed |
| Punicic acid alleviates osteoarthritis progression through miR-29a-3p-dependent inhibition of the MAP2K6/p38 MAPK pathway. | In Vitro Cell Dev Biol Anim | 2026 | 42747754 | PubTator, text mining | PubMed |
| Donor-dependent heterogeneity and matrix-remodeling transcriptional programs in COL2A1-variant urine-derived cell cultures with IGF1-associated cell-state shifts. | Front Cell Dev Biol | 2026 | 42745831 | PubTator, text mining | PubMed |
Rivaroxaban suppresses factor Xa-Driven PAR-2-ERK inflammatory, catabolic, osteoclastogenic, and mitochondrial dysfunction signaling in osteoarthritis-relevant chondrocytes: a drug-repurposing strategy for joint inflammation. | Front Pharmacol | 2026 | 42741326 | PubTator, text mining | PubMed |
| Synovial fluid and serum levels of a disintegrin and metalloproteinase with thrombospondin motifs 5 are associated with the severity of primary knee osteoarthritis. | Clin Biomech (Bristol) | 2026 | 42731244 | PubTator, text mining | PubMed |
| Eugenol preserves chondrocyte extracellular matrix homeostasis by modulating the ALK1/ALK5-associated TGF-β/Smad signaling axis. | Front Pharmacol | 2026 | 42723961 | PubTator, text mining | PubMed |
| In vitro evaluation of hydroxyapatite, β-tricalcium phosphate, graphene oxide and zinc oxide for osteochondral regeneration under inflammatory conditions. | Mol Cell Biochem | 2026 | 42709332 | PubTator, text mining | PubMed |
| Early mRNA expression of pro-inflammatory cytokines and ADAMTS-5 in an acute ischemia/reperfusion-induced pressure ulcer model, a pilot exploratory animal study. | Turk J Phys Med Rehabil | 2026 | 42682030 | PubTator, text mining | PubMed |
| Plasma miR-148b-3p is associated with CKD-related renal dysfunction and carotid plaque burden in patients with established coronary artery disease. | Front Cardiovasc Med | 2026 | 42656636 | PubTator, text mining | PubMed |
| Physiological Lipid Palmitoylcarnitine Constrains Factor Xa Signalling Through PAR-2 to Attenuate ERK-Driven Inflammation and Preserve Mitochondrial Membrane Potential in Chondrocytes. | Biomedicines | 2026 | 42652063 | PubTator, text mining | PubMed |
1 to 10 of 3,260
See all 3,260 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/11096
GET https://conductscience.org/api/genes/v1/11096/patents?page=2